The DOI matches its Crossref record; 120 of the 120 references it cites were found in a registry or an index.
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Open accessAbstract
Antibodies are important therapeutic agents for cancer. Recently, it has become clear that antibodies possess several clinically relevant mechanisms of action. Many clinically useful antibodies can manipulate tumour-related signalling. In addition, antibodies exhibit various immunomodulatory properties and, by directly activating or inhibiting molecules of the immune system, antibodies can promote the induction of antitumour immune responses. These immunomodulatory properties can form the basis for new cancer treatment strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · cited 1×
“A seminal paper showed that the antitumour activities of trastuzumab and rituximab (Rituxan/Mabthera; Genentech/Roche/Biogen Idec) were lower in FcγR-deficient mice than wild-type mic”
BackgroundMcLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,755
Trastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,585
Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
Albert, M. L., Sauter, B., & Bhardwaj, N. (1998) · Nature · doi:10.1038/32183 · Cited by 2,349
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346
Regulatory T cells, tumour immunity and immunotherapy
Zou, W. (2006) · Nature Reviews Immunology · doi:10.1038/nri1806 · Cited by 2,085
Bonner, J. A., Harari, P. M., Giralt, J., Cohen, R. B., Jones, C. U., Sur, R. K., Raben, D., Baselga, J., Spencer, S. A., Zhu, J., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70311-0 · Cited by 1,978
Complement and its role in innate and adaptive immune responses
Dunkelberger, J. R., & Song, W.-C. (2010) · Cell Research · doi:10.1038/cr.2009.139 · Cited by 1,932
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Immunosuppressive Strategies that are Mediated by Tumor Cells
Rabinovich, G. A., Gabrilovich, D., & Sotomayor, E. M. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,702
VEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673
Molecular mechanism and function of CD40/CD40L engagement in the immune system
Elgueta, R., Benson, M. J., De Vries, V. C., Wasiuk, A., Guo, Y., & Noelle, R. J. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00782.x · Cited by 1,625
Weng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300
Complement regulators and inhibitory proteins
Zipfel, P. F., & Skerka, C. (2009) · Nature Reviews Immunology · doi:10.1038/nri2620 · Cited by 1,264
Monoclonal antibody therapy of cancer
Adams, G. P., & Weiner, L. M. (2005) · Nature Biotechnology · doi:10.1038/nbt1137 · Cited by 1,246
Self-citationLamon, D. E. J. S., Eyland, B. R. L., Hak, S. T. S., Uchs, H. A. F., Aton, V. I. P., Ajamonde, A. L. B., LeMing, T., Iermann, W. O. E., Olter, J. A. W., Egram, M. A. P., et al. (2009) · Cited by 1,199
Witzig, T. E., Gordon, L. I., Cabanillas, F., Czuczman, M. S., Emmanouilides, C., Joyce, R., Pohlman, B. L., Bartlett, N. L., Wiseman, G. A., Padre, N., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.076 · Cited by 1,170
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
Franklin, M. C., Carey, K. D., Vajdos, F. F., Leahy, D. J., de Vos, A. M., & Sliwkowski, M. X. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00083-2 · Cited by 1,120
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
Li, S., Schmitz, K. R., Jeffrey, P. D., Wiltzius, J. J. W., Kussie, P., & Ferguson, K. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.003 · Cited by 1,118
Immune infiltration in human tumors: a prognostic factor that should not be ignored
Pagès, F., Galon, J., Dieu-Nosjean, M.-C., Tartour, E., Sautès-Fridman, C., & Fridman, W.-H. (2010) · Oncogene · doi:10.1038/onc.2009.416 · Cited by 1,087
Fcγ Receptors: Old Friends and New Family Members
Nimmerjahn, F., & Ravetch, J. V. (2006) · Immunity · doi:10.1016/j.immuni.2005.11.010 · Cited by 1,072
Onizuka, S., Tawara, I., Shimizu, J., Sakaguchi, S., Fujita, T., & Nakayama, E. (1999) · PubMed · Cited by 1,062
van Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020 · cited 1×
“Using irradiated GM-CSF-producing B16 melanoma cells as a vaccination strategy, it was shown that the addition of CTLA4-specific antibody was more effective at eradicating established B16 tumours than vaccination alon”
BackgroundIL-23 promotes tumour incidence and growth
Langowski, J. L., Zhang, X., Wu, L., Mattson, J. D., Chen, T., Smith, K., Basham, B., McClanahan, T., Kastelein, R. A., & Oft, M. (2006) · Nature · doi:10.1038/nature04808 · Cited by 1,018
Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981
Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082492 · Cited by 967
Blackwell, K. L., Burstein, H. J., Storniolo, A. M., Rugo, H., Sledge, G., Koehler, M., Ellis, C., Casey, M., Vukelja, S., Bischoff, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4437 · Cited by 942
Engineered antibody Fc variants with enhanced effector function
Lazar, G. A., Dang, W., Karki, S., Vafa, O., Peng, J. S., Hyun, L., Chan, C., Chung, H. S., Eivazi, A., Yoder, S. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508123103 · Cited by 803
T Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor Immunity
Martin-Orozco, N., Muranski, P., Chung, Y., Yang, X. O., Yamazaki, T., Lu, S., Hwu, P., Restifo, N. P., Overwijk, W. W., & Dong, C. (2009) · Immunity · doi:10.1016/j.immuni.2009.09.014 · Cited by 800
Hirschi, K. K., Rohovsky, S. A., & D'Amore, P. A. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.141.3.805 · Cited by 796
CD40/CD154 Interactions at the Interface of Tolerance and Immunity
Quezada, S. A., Jarvinen, L. Z., Lind, E. F., & Noelle, R. J. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104533 · Cited by 683
Berger, R., Rotem-Yehudar, R., Slama, G., Landes, S., Kneller, A., Leiba, M., Koren-Michowitz, M., Shimoni, A., & Nagler, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4079 · Cited by 680
Scheuer, W., Friess, T., Burtscher, H., Bossenmaier, B., Endl, J., & Hasmann, M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4597 · Cited by 622
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
Wierda, W. G., Kipps, T. J., Mayer, J., Stilgenbauer, S., Williams, C. D., Hellmann, A., Robak, T., Furman, R. R., Hillmen, P., Trneny, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3187 · Cited by 590
Forstpointner, R. (2004) · Blood · doi:10.1182/blood-2004-04-1323 · Cited by 580
Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo
Di Gaetano, N., Cittera, E., Nota, R., Vecchi, A., Grieco, V., Scanziani, E., Botto, M., Introna, M., & Golay, J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.3.1581 · Cited by 576
Kaminski, M. S., Estes, J., Zasadny, K. R., Francis, I. R., Ross, C. W., Tuck, M., Regan, D., Fisher, S., Gutierrez, J., Kroll, S., et al. (2000) · Blood · doi:10.1182/blood.v96.4.1259 · Cited by 525
From the bench to the bedside: ways to improve rituximab efficacy
Cartron, G., Watier, H., Golay, J., & Solal-Celigny, P. (2004) · Blood · doi:10.1182/blood-2004-03-1110 · Cited by 523
Bibeau, F., Lopez-Crapez, E., Di Fiore, F., Thezenas, S., Ychou, M., Blanchard, F., Lamy, A., Penault-Llorca, F., Frébourg, T., Michel, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0463 · Cited by 521
Sievers, E. L., Appelbaum, F. R., Spielberger, R. T., Forman, S. J., Flowers, D., Smith, F. O., Shannon-Dorcy, K., Berger, M. S., & Bernstein, I. D. (1999) · Blood · doi:10.1182/blood.v93.11.3678 · Cited by 512
Willett, C. G., Duda, D. G., di Tomaso, E., Boucher, Y., Ancukiewicz, M., Sahani, D. V., Lahdenranta, J., Chung, D. C., Fischman, A. J., Lauwers, G. Y., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.1771 · Cited by 508
Lundin, J., Kimby, E., Björkholm, M., Broliden, P.-A., Celsing, F., Hjalmar, V., Möllgård, L., Rebello, P., Hale, G., Waldmann, H., et al. (2002) · Blood · doi:10.1182/blood-2002-01-0159 · Cited by 497
Scaltriti, M., Verma, C., Guzman, M., Jimenez, J., Parra, J. L., Pedersen, K., Smith, D. J., Landolfi, S., Ramon y Cajal, S., Arribas, J., et al. (2009) · Oncogene · doi:10.1038/onc.2008.432 · Cited by 439
Small, E. J., Tchekmedyian, N. S., Rini, B. I., Fong, L., Lowy, I., & Allison, J. P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2318 · Cited by 407
Coiffier, B., Lepretre, S., Pedersen, L. M., Gadeberg, O., Fredriksen, H., van Oers, M. H. J., Wooldridge, J., Kloczko, J., Holowiecki, J., Hellmann, A., et al. (2008) · Blood · doi:10.1182/blood-2007-09-111781 · Cited by 387
Gulley, J. L., Arlen, P. M., Bastian, A., Morin, S., Marte, J., Beetham, P., Tsang, K.-Y., Yokokawa, J., Hodge, J. W., Ménard, C., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2062 · Cited by 370
Schoeberl, B., Pace, E. A., Fitzgerald, J. B., Harms, B. D., Xu, L., Nie, L., Linggi, B., Kalra, A., Paragas, V., Bukhalid, R., et al. (2009) · Science Signaling · doi:10.1126/scisignal.2000352 · Cited by 360
Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents
Cragg, M. S., & Glennie, M. J. (2004) · Blood · doi:10.1182/blood-2003-06-2031 · Cited by 360
Dhodapkar, K. M., Krasovsky, J., Williamson, B., & Dhodapkar, M. V. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011097 · Cited by 349
Engineered protein scaffolds as next-generation antibody therapeutics
Gebauer, M., & Skerra, A. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.04.627 · Cited by 341
A Sense of Danger from Radiation1
McBride, W. H., Chiang, C.-S., Olson, J. L., Wang, C.-C., Hong, J.-H., Pajonk, F., Dougherty, G. J., Iwamoto, K. S., Pervan, M., & Liao, Y.-P. (2004) · Radiation Research · doi:10.1667/rr3196 · Cited by 323
Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer
Disis, M. L., Wallace, D. R., Gooley, T. A., Dang, Y., Slota, M., Lu, H., Coveler, A. L., Childs, J. S., Higgins, D. M., Fintak, P. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6789 · Cited by 300
Rech, A. J., & Vonderheide, R. H. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04939.x · Cited by 289
Berard, F., Blanco, P., Davoust, J., Neidhart-Berard, E.-M., Nouri-Shirazi, M., Taquet, N., Rimoldi, D., Cerottini, J. C., Banchereau, J., & Palucka, A. K. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.11.1535 · Cited by 284
Shrikant, P., Khoruts, A., & Mescher, M. F. (1999) · Immunity · doi:10.1016/s1074-7613(00)80123-5 · Cited by 283
Dependence of antibody-mediated presentation of antigen on FcRn
Qiao, S.-W., Kobayashi, K., Johansen, F.-E., Sollid, L. M., Andersen, J. T., Milford, E., Roopenian, D. C., Lencer, W. I., & Blumberg, R. S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801717105 · Cited by 280
Matar, P., Rojo, F., Cassia, R., Moreno-Bueno, G., Di Cosimo, S., Tabernero, J., Guzmán, M., Rodriguez, S., Arribas, J., Palacios, J., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0870 · Cited by 277
Horton, H. M., Bernett, M. J., Pong, E., Peipp, M., Karki, S., Chu, S. Y., Richards, J. O., Vostiar, I., Joyce, P. F., Repp, R., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2268 · Cited by 272
BiTEs: bispecific antibody constructs with unique anti-tumor activity
Wolf, E., Hofmeister, R., Kufer, P., Schlereth, B., & Baeuerle, P. A. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03554-3 · Cited by 260
Brischwein, K., Schlereth, B., Guller, B., Steiger, C., Wolf, A., Lutterbuese, R., Offner, S., Locher, M., Urbig, T., Raum, T., et al. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2005.07.034 · Cited by 256
Sunada, H., Magun, B. E., Mendelsohn, J., & MacLeod, C. L. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.11.3825 · Cited by 253
Dhodapkar, K. M., Kaufman, J. L., Ehlers, M., Banerjee, D. K., Bonvini, E., Koenig, S., Steinman, R. M., Ravetch, J. V., & Dhodapkar, M. V. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500014102 · Cited by 241
Yeung, Y. A., Leabman, M. K., Marvin, J. S., Qiu, J., Adams, C. W., Lien, S., Starovasnik, M. A., & Lowman, H. B. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804182 · Cited by 237
Hoffmann, T. K., Meidenbauer, N., Dworacki, G., Kanaya, H., & Whiteside, T. L. (2000) · PubMed · Cited by 227
Ipilimumab: controversies in its development, utility and autoimmune adverse events
Weber, J. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0653-8 · Cited by 224
Scott, A. M., Lee, F.-T., Tebbutt, N., Herbertson, R., Gill, S. S., Liu, Z., Skrinos, E., Murone, C., Saunder, T. H., Chappell, B., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611693104 · Cited by 222
Augmented HER-2–Specific Immunity during Treatment with Trastuzumab and Chemotherapy
Taylor, C., Hershman, D., Shah, N., Suciu-Foca, N., Petrylak, D. P., Taub, R., Vahdat, L., Cheng, B., Pegram, M., Knutson, K. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0507 · Cited by 213
Advani, R., Forero-Torres, A., Furman, R. R., Rosenblatt, J. D., Younes, A., Ren, H., Harrop, K., Whiting, N., & Drachman, J. G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.3017 · Cited by 188
Collected Studies on Immunity.
(1906) · Journal of the American Medical Association · doi:10.1001/jama.1906.02520030066027 · Cited by 177
OX40 Agonist Therapy Enhances CD8 Infiltration and Decreases Immune Suppression in the Tumor
Gough, M. J., Ruby, C. E., Redmond, W. L., Dhungel, B., Brown, A., & Weinberg, A. D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6484 · Cited by 174
Racila, E. V., Link, B. K., Weng, W., Witzig, T. E., Ansell, S. M., Maurer, M. J., Huang, J., Dahle, C. E., Halwani, A. S., Levy, R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0745 · Cited by 159
Molckovsky, A., & Siu, L. L. (2008) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-1-20 · Cited by 159
Engineered therapeutic antibodies with improved effector functions
Kubota, T., Niwa, R., Satoh, M., Akinaga, S., Shitara, K., & Hanai, N. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01222.x · Cited by 156
Wu, Y. L., Zhong, Z., Huber, J., Bassi, R., Finnerty, B., Corcoran, E., Li, H., Navarro, E. C., Balderes, P. J., Jimenez, X., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0831 · Cited by 152
Ehrlich, P., Bolduan, C. F., & Howard (1907) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-190708000-00032 · Cited by 152
Gilman, A. L., Ozkaynak, M. F., Matthay, K. K., Krailo, M., Yu, A. L.-T., Gan, J., Sternberg, A. G., Hank, J. A., Seeger, R. C., Reaman, G. H., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.3564 · Cited by 151
Wang, S., Veeramani, S., Racila, E. V., Cagley, J. R., Fritzinger, D. C., Vogel, C.-W., John, W. S., & Weiner, G. J. (2009) · Blood · doi:10.1182/blood-2009-01-200469 · Cited by 143
Self-citationDose and Schedule Study of Panitumumab Monotherapy in Patients with Advanced Solid Malignancies
Weiner, L. M., Belldegrun, A. S., Crawford, J., Tolcher, A. W., Lockbaum, P., Arends, R., Navale, L., Amado, R. G., Schwab, G. M., & Figlin, R. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1509 · Cited by 136
Self-citationShahied, L., Tang, Y., Alpaugh, R. K., Somer, R. A., Greenspon, D., & Weiner, L. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407888200 · Cited by 120
Self-citationImmunogenic anti-cancer chemotherapy as an emerging concept
Haynes, N. M., der Most, R. G. V., Lake, R., & Smyth, M. J. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.05.008 · Cited by 114
Terabe, M., Ambrosino, E., Takaku, S., O’Konek, J. J., Venzon, D. J., Lonning, S. M., McPherson, J. M., & Berzofsky, J. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1066 · Cited by 112
Khan, K. D., Emmanouilides, C. E., Benson, D. M., Hurst, D., Garcia, P., Michelson, G. C., Milan, S., Ferketich, A. K., Piro, L. D., Leonard, J. P., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1571 · Cited by 105
Zalevsky, J., Leung, I., Karki, S., Chu, S. Y., Zhukovsky, E. A., Desjarlais, J. R., Carmichael, D. F., & Lawrence, C. E. (2008) · Blood · doi:10.1182/blood-2008-10-182048 · Cited by 102
Krupitskaya, Y., & Wakelee, H. A. (2009) · PubMed · Cited by 98
Strategies to target HER2/neu overexpression for cancer therapy
Chen, J., Lan, K., & Hung, M. (2003) · Drug Resistance Updates · doi:10.1016/s1368-7646(03)00040-2 · Cited by 90
Murillo, O., Arina, A., Hervás‐Stubbs, S., Gupta, A., McCluskey, B., Dubrot, J., Palazón, A., Azpilikueta, A., Ochoa, M. C., Alfaro, C., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0285 · Cited by 87
Kuenen, B. C., Witteveen, P. O., Ruijter, R., Giaccone, G., Dontabhaktuni, A., Fox, F. E., Katz, T. L., Youssoufian, H., Zhu, J., Rowinsky, E. K., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2425 · Cited by 87
Blockade of TGF‐β enhances tumor vaccine efficacy mediated by CD8+ T cells
Takaku, S., Terabe, M., Ambrosino, E., Peng, J., Lonning, S. M., McPherson, J. M., & Berzofsky, J. A. (2009) · International Journal of Cancer · doi:10.1002/ijc.24961 · Cited by 83
Anti-CD40 agonist antibodies: Preclinical and clinical experience
Khalil, M., & Vonderheide, R. H. (2007) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2007.06.001 · Cited by 81
Oflazoglu, E., Stone, I. J., Brown, L. L., Gordon, K. A., van Rooijen, N., Jonas, M., Law, C.-L., Grewal, I. S., & Gerber, H.-P. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604812 · Cited by 81
Mamluk, R., Carvajal, I. M., Morse, B. A., Wong, H. K., Abramowitz, J., Aslanian, S., Lim, A.-C., Gokemeijer, J., Storek, M., Lee, J., et al. (2010) · mAbs · doi:10.4161/mabs.2.2.11304 · Cited by 79
Radiation therapy and Toll-like receptor signaling: implications for the treatment of cancer
Roses, R. E., Xu, M., Koski, G. K., & Czerniecki, B. J. (2008) · Oncogene · doi:10.1038/sj.onc.1210909 · Cited by 74
Huang, X., Wong, M. K. K., Yi, H., Watkins, S. C., Laird, A., Wolf, S. F., & Gorelik, E. (2002) · PubMed · Cited by 72
Recent Advances Using Anti-CTLA-4 for the Treatment of Melanoma
Sarnaik, A. A., & Weber, J. S. (2009) · The Cancer Journal · doi:10.1097/ppo.0b013e3181a7450f · Cited by 64
Shen, J., Vil, M. D., Prewett, M. C., Damoci, C., Zhang, H., Li, H., Jimenez, X., Deevi, D. S., Iacolina, M. D., Kayas, A., et al. (2009) · Neoplasia · doi:10.1593/neo.09278 · Cited by 64
van der Kolk, L. E., Grillo-López, A. J., Baars, J. W., & van Oers, M. H. J. (2003) · Leukemia · doi:10.1038/sj.leu.2402995 · Cited by 64
Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms
Hollmén, M., Määttä, J. A., Bald, L. N., Sliwkowski, M. X., & Elenius, K. (2009) · Oncogene · doi:10.1038/onc.2008.481 · Cited by 56
A cytokine-neutralizing antibody as a structural mimetic of 2 receptor interactions
Grütter, C., Wilkinson, T. C. I., Turner, R., Podichetty, S., Finch, D. K., McCourt, M., Loning, S., Jermutus, L., & Grütter, M. G. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807200106 · Cited by 56
Ramalingam, S. S., Forster, J., Naret, C., Evans, T. L., Sulecki, M., Lu, H., Teegarden, P., Weber, M. R., & Belani, C. P. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181653d1b · Cited by 54
Li, D., Ji, H., Zaghlul, S., McNamara, K. L., Liang, M., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L. R., Padera, R. F., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30446 · Cited by 53
Petrausch, U., Jensen, S. M., Twitty, C., Poehlein, C. H., Haley, D. P., Walker, E., & Fox, B. A. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900560 · Cited by 36
Hong, H. Y., Gu, Y., Zhang, H., Simon, A. K., Chen, X., Wu, C. Y., Xu, X.-N., & Jiang, S. (2009) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2009.04018.x · Cited by 35
Rudge, G., Barrett, S. P., Scott, B., & van Driel, I. R. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.7.4089 · Cited by 34
Tassi, E., Braga, M., Longhi, R., Gavazzi, F., Parmiani, G., Carlo, V. D., & Protti, M. P. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007234 · Cited by 32
Immunostimulatory CpG oligodeoxynucleotides and antibody therapy of cancer
Jahrsdörfer, B., & Weiner, G. J. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)00236-7 · Cited by 30
Mackey, J. R., Gelmon, K. A., Martín, M., McCarthy, N. J., Pintér, T., Rupin, M., & Youssoufian, H. (2009) · Clinical Breast Cancer · doi:10.3816/cbc.2009.n.044 · Cited by 28
Cetuximab and panitumumab: are they interchangeable?
Kim, R. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70312-2 · Cited by 25
Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/α-interferon
Alpaugh, R. K., von Mehren, M., Palazzo, I., Atkins, M. B., Sparano, J. A., Schuchter, L. M., Weiner, L. M., & Dutcher, J. P. (1998) · Medical Oncology · doi:10.1007/bf02821938 · Cited by 24
Self-citationGan, H. K., Lappas, M., Cao, D. X., Cvrljevdic, A., Scott, A. M., & Johns, T. G. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00783.x · Cited by 24
Cited by
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
“Squamous subtype 3 4 0 0 (0-60) NA 1 25 (0-81) 50 (1-99)”
Molecular mechanisms of T cell co-stimulation and co-inhibition
Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3236 · Cited by 2,160
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Sanmamed, M. F., & Chen, L. (2018) · Cell · doi:10.1016/j.cell.2018.09.035 · Cited by 1,392
Molecular targeted therapy: Treating cancer with specificity
Lee, Y. T., Tan, Y. J., & Oon, C. E. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.07.034 · Cited by 1,067
Metadata
- Authors
- Weiner, L. M., Surana, R., & Wang, S.
- Venue
- Nature Reviews Immunology
- Published
- 2010-05
- Volume
- 10
- Issue
- 5
- Pages
- 317-327
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W1965205681
- Cited by
- 1,283
- References
- 120
- FWCI
- 8.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.